1. Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody. (20th November 2022) Authors: Regidor, Bernard Sean; Siddiqi, Dilawer; Beatty, Bethany Marie; Goldwater, Marissa‐Skye; Jew, Scott; Bujarski, Sean; Swift, Regina; Kim, Susanna; Berenson, James R. Journal: European journal of haematology Issue: Volume 110:Number 2(2023) Page Start: 222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. (9th December 2022) Authors: Berenson, James R.; Martinez, Daisy; Safaie, Tahmineh; Boccia, Ralph; Yang, Honghao; Moezi, Mehdi; Lim, Stephen; Schwartz, Gary; Eshaghian, Shahrooz; Swift, Regina; Eades, Benjamin M.; Bujarski, Sean; Regidor, Bernard; Kim, Clara; Kim, Susanna; Vescio, Robert Journal: British journal of haematology Issue: Volume 200:Number 6(2023) Page Start: 722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma. (January 2023) Authors: Goldwater, Marissa-Skye; Stampfer, Samuel D.; Sean Regidor, Bernard; Bujarski, Sean; Jew, Scott; Chen, Haiming; Xu, Ning; Kim, Clara; Kim, Susanna; Berenson, James R. Journal: Clinical infection in practice Issue: Volume 17(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗